Abstract | PURPOSE: PATIENTS AND METHODS: In a prospective, randomized, open-label, controlled multicenter study, 60 patients younger than age 46 years with hormone-insensitive breast cancer were allocated to receive anthracycline/ cyclophosphamide (with or without taxane) -based neoadjuvant chemotherapy with or without goserelin. The first goserelin injection was administered at least 2 weeks before the first chemotherapy cycle, continuing at 3.6 mg subcutaneously every 4 weeks until the end of the last cycle. The primary objective was the reappearance of normal ovarian function, defined as two consecutive menstrual periods within 21 to 35 days at 6 months after end of chemotherapy. RESULTS: Fifty-three patients (88.3%) experienced temporary amenorrhea (93.3% with v 83.3% without goserelin). No significant difference was observed regarding the reappearance of menstruation at 6 months after chemotherapy (70.0% with v 56.7% without goserelin; difference of 13.3%; 95% CI, -10.85 to 37.45; P = .284). All but one evaluable patient reported regular menses at 2 years after chemotherapy. Time to restoration of menstruation was 6.8 months (95% CI, 5.2 to 8.4) with goserelin and 6.1 months (95% CI, 5.3 to 6.8) without goserelin (P = .304). Chemotherapy resulted in a decreased ovarian reserve measured by inhibin B and anti-Müllerian hormone during follow-up, supporting the other findings. CONCLUSION:
|
Authors | Bernd Gerber, Gunter von Minckwitz, Heinrich Stehle, Toralf Reimer, Ricardo Felberbaum, Nikolai Maass, Dorothea Fischer, Harald L Sommer, Bettina Conrad, Olaf Ortmann, Tanja Fehm, Mahdi Rezai, Keyur Mehta, Sibylle Loibl, German Breast Group Investigators |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 29
Issue 17
Pg. 2334-41
(Jun 10 2011)
ISSN: 1527-7755 [Electronic] United States |
PMID | 21537042
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Goserelin
- Anti-Mullerian Hormone
|
Topics |
- Adult
- Anti-Mullerian Hormone
(blood)
- Antineoplastic Agents, Hormonal
(pharmacology)
- Breast Neoplasms
(blood, drug therapy, physiopathology)
- Chemotherapy, Adjuvant
- Female
- Goserelin
(pharmacology)
- Humans
- Menstruation
(drug effects)
- Middle Aged
- Ovary
(drug effects, physiopathology)
|